JUNS
JUPITER NEUROSCIENCES, INC.
$0.28
▲ +18.34%$0.28▼ -76.67%
over 1Y
L $0.21EODHDH $2.97
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+18.3%
1W+21.7%
1M+16.7%
3M-20.0%
YTD-72.3%
1Y-76.7%
Avoid
Conviction
Horizon
Medium (3–12mo)
Street · 7 analysts
Buy
Conservative balance sheet (liabilities/equity -4.04x); but unprofitable (net margin -39662.8%).
Revenue (FY2025) $21.8K · FY2025
JUPITER NEUROSCIENCES, INC. shows $21.8K in FY2025 revenue, a -39662.8% net margin.
Financials · annual, by fiscal year
| Line item | FY23 | FY24 | FY25 |
|---|---|---|---|
| Revenue | — | — | $21.8K |
| Gross profit | — | — | $17.6K |
| Operating income | -$3.87M | -$3.09M | -$8.91M |
| Net income | -$4.78M | -$2.44M | -$8.64M |
| Diluted EPS | -$0.18 | -$0.08 | -$0.25 |
| Net margin | — | — | -39662.8% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$10.2M
EV / EBITDA—
EV / Sales466.1
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-85.1%
FCF yield—
Quality & risk
ROIC (est.)—
Free cash flow—
Total debt—
Net cash—
Altman Z-Score-13.73 distress
Piotroski F-Score1/6
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+9.6%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
- S-1 Securities registration2026-06-26
- 8-K Officer / director change2026-06-22
- DEF 14A Proxy statement2026-06-22
- 8-K Officer / director change2026-06-05
- 8-K Material agreement2026-05-21
- 8-K Reg FD disclosure2026-05-20
- 10-Q Quarterly report2026-05-14
- S-3 Shelf registration (potential raise)2026-04-16
- 10-K Annual report2026-04-01
Recent filings
all on EDGAR ↗S-1Filing2026-06-26open ↗ARSPeriod ending 2025-12-312026-06-22open ↗DEF 14APeriod ending 2026-06-222026-06-22open ↗424B3Filing2026-06-22open ↗8-KPeriod ending 2026-06-172026-06-22open ↗PRE 14APeriod ending 2026-06-092026-06-09open ↗424B3Filing2026-06-05open ↗8-KPeriod ending 2026-06-022026-06-05open ↗4Period ending 2026-06-022026-06-05open ↗4Period ending 2026-06-022026-06-04open ↗4Period ending 2026-06-022026-06-04open ↗4Period ending 2026-06-022026-06-04open ↗
Frequently asked
- Is JUPITER NEUROSCIENCES, INC. (JUNS) a buy?
- JUNS currently carries a Avoid rating with 3/5 conviction, derived from its latest SEC filings. Conservative balance sheet (liabilities/equity -4.04x); but unprofitable (net margin -39662.8%).
- What is JUPITER NEUROSCIENCES, INC.'s quality score?
- JUNS scores 18.941176470588236/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001679628, latest 10-Q filed 2026-05-14) · EODHD · as of 6/26/2026, 1:02:10 AM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.